Ontology highlight
ABSTRACT:
SUBMITTER: Nayak L
PROVIDER: S-EPMC4802006 | biostudies-literature | 2013 Jan
REPOSITORIES: biostudies-literature
Leukemia & lymphoma 20120709 1
We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies. Treatment consisted of an induction phase with rituximab (750 mg/m(2)) on days 1, 8, 15 and 22 and temozolomide (150 mg/m(2)) days 1-7 and 15-21, followed by six cycles of consolidation temozolomide (150-200 mg/m(2) × 5/28 days), followed by maintenance ...[more]